Abramson Cancer Center of the University of Pennsylvania
Last Modified: April 24, 2007
You may also use Quicktime to view the individual presentation:
Head and Neck
Robert Malyapa, M.D., Assistant Professor, Department of Radiation Oncology, University of Florida Proton Therapy Institute, Jacksonville, FL
iTunes Manual Instructions:
Sep 19, 2014 - The investigational drug alpelisib (previously known as BYL719) appears to inhibit activation of the pathway that leads to resistance to cetuximab, an anti-epidermal growth factor receptor agent used in the treatment of head and neck cancer. These findings were presented at the American Association for Cancer Research's special conference "Targeting the PI3K-mTOR Network in Cancer," held from Sept. 14 to 17 in Philadelphia.